Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49

Trial Profile

Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2013

At a glance

  • Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2011 Results published in Vaccine.
    • 13 Jan 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Actual patient number (4648) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top